Rhythm Pharmaceuticals, Inc.
bivamelagon
acquired hypothalamic obesity
Countdown
177days
Catalyst readout · ~ Dec 31, 2026 estimated
What's at stake
A key catalyst for bivamelagon (acquired hypothalamic obesity) is expected ~ Dec 31, 2026.
Primary source
· SEC 8-K
verified 15h ago
“initiate a pivotal Phase 3 trial evaluating bivamelagon in acquired HO in 2026.”